FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Haematologica

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15257945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

  2003cited by this paper
• Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia.

  2003cited by this paper
• Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.

  2003cited by this paper
• CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

  2003cited by this paper
• Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease.

  2003cited by this paper
• Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.

  2002cited by this paper
• Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia.

  2002cited by this paper
• Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.

  2000cited by this paper
• Multilineage involvement and erythropoietin-"independent" erythroid progenitor cells in a patient with systemic mastocytosis

  1998cited by this paper
• Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase.

  1996cited by this paper

• Mastocitosis

  2025cites this paper
• Mastocytoses

  2024cites this paper
• Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management

  2021cites this paper
• Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management

  2018cites this paper
• A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience

  2018cites this paper
• CME Information

  2016cites this paper
• Myeloid Neoplasms with Eosinophil Lineage

  2016cites this paper
• Mastocytoses systémiques : aspects cytologiques et histologiques en hématologie

  2016cites this paper
• Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice

  2016cites this paper
• Systemic Mastocytosis and Mast Cell Tumors

  2016influential citation
• Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management

  2016cites this paper
• CME Information: Systemic mastocytosis in adults: 2015 update on diagnosis, risk-stratification, and management

  2015cites this paper
• KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.

  2015cites this paper
• The genetic basis of mast cell activation disease - looking through a glass darkly.

  2015cites this paper
• [Mastocytosis].

  2014cites this paper
• CME Information

  2013cites this paper
• Spanish Network on Mastocytosis (REMA) in a series of 113 patients lineages in systemic mast cell disorders: a prospective study of the KIT mutation in mast cells and other bone marrow hematopoietic cell

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.

  2013cites this paper
• Mastocytoses

  2013cites this paper
• Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management

  2012cites this paper
• Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management

  2011cites this paper
• Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.

  2011cites this paper
• Continuing medical education program i n American Journal of Hematology

  2011cites this paper
• Perturbations du métabolisme oxydatif induites par l’activation de PDGFRα : mécanismes et conséquences dans la leucémie chronique à éosinophiles FIP1L1-PDGFRA

  2011cites this paper
• FIP 1 L 1 / PDGFR-Associated Systemic Mastocytosis

  2010cites this paper
• FIP1L1/PDGFRα-Associated Systemic Mastocytosis

  2010cites this paper
• Philadelphia chromosome-negative chronic myeloproliferative disease.

  2009cites this paper
• The 2008 World Health Organization classification system for myeloproliferative neoplasms

  2009cites this paper
• Advances in Understanding and Management of Myeloproliferative Neoplasms

  2009cites this paper
• Murine Model of Hypereosinophilic Syndromes/Chronic Eosinophilic Leukemia

  2009cites this paper
• Chronic eosinophilic leukemia/hypereosinophilic syndrome.

  2008cites this paper
• Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

  2008cites this paper
• Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1

  2008cites this paper
• FIP 1 L 1 / PDGFR α synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia / hypereosinophilic syndrome Running title : FIP 1 L 1-PDGFRA-induced systemic mastocytosis

  2008cites this paper
• Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms

  2008cites this paper
• FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome.

  2008cites this paper
• How we diagnose and treat WHO-defined systemic mastocytosis in adults

  2008cites this paper
• KIT and Mastocytosis

  2008cites this paper
• Rare Hematological Malignancies

  2008cites this paper
• Synchronous FIP1L1–PDGFRA‐positive chronic eosinophilic leukemia and T‐cell lymphoblastic lymphoma: a bilineal clonal malignancy

  2007cites this paper
• Oncogenes in Myeloproliferative Disorders

  2007cites this paper
• Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

  2006cites this paper
• KIT mutations in mastocytosis and their potential as therapeutic targets.

  2006cites this paper
• KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.

  2006cites this paper
• The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera

  2006cites this paper
• Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

  2006cites this paper
• Tetracycline Regulated Systems in Functional Oncogenomics

  2006cites this paper
• Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.

  2006cites this paper
• The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

  2006cites this paper
• Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA‐positive hypereosinophilic syndrome

  2006cites this paper
• Current Concepts on the Pathogenesis of the Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia

  2006cites this paper
• Novel approaches in the treatment of systemic mastocytosis

  2006cites this paper
• First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.

  2006cites this paper
• First Case of an AIDS Patient With Systemic Mast Cell Disease Associated With Eosinophilia FIP1-Positive Treated With Imatinib Mesylate Therapy

  2006cites this paper
• The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

  2005cites this paper
• Clonality and Molecular Pathogenesis of Mastocytosis

  2005cites this paper
• Polycythemia vera: scientific advances and current practice.

  2005cites this paper
• Molecular Classification and Pathogenesis of Eosinophilic Disorders: 2005 Update

  2005cites this paper
• The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

  2005cites this paper
• JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance

  2005cites this paper
• Mastocytoses systémiques : leurs traitements

  2005cites this paper
• Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics

  2005cites this paper
• Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis.

  2005cites this paper